Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection

Hepatology

Volumn 53, Issue 3, 2011, Pages 1067-1068

  Lagging, Martin ^a   Alsiö, Åsa ^a   Langeland, Nina ^b   Pedersen, Court ^c   Färkkilä, Martti ^d   Buhl, Mads Rauning ^e   Mørch, Kristine ^b   Hellstrand, Kristoffer ^a   Norkrans, Gunnar ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF HELSINKI   (Finland)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; POLYETHYLENE GLYCOLS; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 79952211356     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23962     Document Type: Letter

References (2)

1. Diago M, Shiffman ML, Bronowicki JP, Zeuzem S, Rodriguez-Torres M, Pappas SC, et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. HEPATOLOGY 2010; 51: 1897-1903.
2. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. HEPATOLOGY 2008; 47: 1837-1845.